Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron supplementation, multiple micronutrient powders, and dihydroartemisinin-piperaquine for infant anaemia and neurodevelopment
ACTRN12620000386932Phase 3Completed
- Sponsor
- Kamuzu University of Health Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of dihydroartemisinin + piperaquine and ferrous sulfate in iron deficiency anemia (IDA), anaemia and malaria (4 arms), sponsored by Kamuzu University of Health Sciences. Primary endpoint: Cognitive development. Started Apr 2020; status: completed.
02
Drugs
dihydroartemisinin + piperaquineferrous sulfate
03
Conditions
iron deficiency anemia (IDA)anaemiamalaria
Beyond the preview
Go deeper on ACTRN12620000386932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000386932.